Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September
Allena Pharmaceuticals (NASDAQ: ALNA) announced participation in two investor conferences this September. Management will take part in the Baird 2020 Global Healthcare Conference on September 10 at 9:40 a.m. ET and the H.C. Wainwright & Co. 22nd Annual Global Investor Conference on September 15 at 12:30 p.m. ET. Live audio webcasts for both events will be accessible on the company’s website, with replays available for 30 days post-presentation. Allena focuses on developing first-in-class oral enzyme therapeutics for rare metabolic and kidney disorders, notably its lead candidate, reloxaliase.
- None.
- None.
NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in fireside chats at two investor conferences in September:
Baird 2020 Global Healthcare Conference
Date: Thursday, September 10
Time: 9:40 a.m. ET
H.C. Wainwright & Co. 22nd Annual Global Investor Conference
Date: Tuesday, September 15
Time: 12:30 p.m. ET
Live audio webcasts of the presentations will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
FAQ
What is Allena Pharmaceuticals' participation in upcoming investor conferences?
What time will Allena Pharmaceuticals present at the Baird conference?
Where can I access the live webcasts for Allena Pharmaceuticals' presentations?
What is reloxaliase developed by Allena Pharmaceuticals?
Will the webcasts of Allena Pharmaceuticals' investor presentations be available later?
